EUVIMEDEUVIMED entdecken
Crossref

Bugbanosides from Cimicifuga racemosa target cyclin-dependent kinase 1 degradation to trigger PANoptosis in liver cancer

Qiang Fu, Yanyuan Qiao, Rong Lu, Yiwen Ding, Xuemei Lin, Yufan Bai, Qiaolin Kang, Pingxian Song, Yong Zhang

Eurasian Journal of Medicine and Oncology · 13.07.2026 · 026110127

DOI: 10.36922/ejmo026110127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 13.07.2026. Verfasst von Qiang Fu und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Liver cancer is a leading cause of cancer-related deaths worldwide, and novel natural-product-based therapeutic strategies are urgently needed. Cimicifuga racemosa is a medicinal plant, and its active components exhibit anti-cancer potential. However, the molecular targets and mechanisms of action in liver cancer remain poorly defined.

Objective

We applied network pharmacology analysis to identify key components of C. racemosa that regulate pyroptosis, apoptosis, and necroptosis (PANoptosis) in liver cancer.

Methods

Transcriptomic data analysis, molecular docking, and experimental approaches were employed to identify cyclin-dependent kinase 1 (CDK1) as a potential target of C. racemosa components. The effects of C. racemosa extracts and purified compounds on CDK1 activity, cell viability, and PANoptosis induction were evaluated in liver cancer cells.

Results

Bugbanosides A, C, and F from C. racemosa were identified as potential CDK1 inhibitors through molecular docking. C. racemosa extracts and these bugbanosides dose-dependently inhibited CDK1 activity, destabilized CDK1 protein, and induced PANoptosis in HepG2 cells, as evidenced by the activation of apoptotic, pyroptotic, and necroptotic markers. Overexpression of CDK1 partially rescued the PANoptosis-inducing effects.

Conclusion

Our study identifies CDK1 as a target of bioactive components from C. racemosa and demonstrates that these components induce PANoptosis in liver cancer cells, suggesting their potential as novel anti-cancer agents for liver cancer treatment.

Zitieren

APA

Fu, Q., Qiao, Y., Lu, R., Ding, Y., Lin, X., Bai, Y., Kang, Q., Song, P., & Zhang, Y. (2026). Bugbanosides from Cimicifuga racemosa target cyclin-dependent kinase 1 degradation to trigger PANoptosis in liver cancer. Eurasian Journal of Medicine and Oncology, 0(0), 026110127. https://doi.org/10.36922/ejmo026110127

Vancouver

Fu Q, Qiao Y, Lu R, Ding Y, Lin X, Bai Y, et al. Bugbanosides from Cimicifuga racemosa target cyclin-dependent kinase 1 degradation to trigger PANoptosis in liver cancer. Eurasian Journal of Medicine and Oncology. 2026;0(0):026110127. doi:10.36922/ejmo026110127

BibTeX
@article{Fu2026,
  author = {Fu, Qiang and Qiao, Yanyuan and Lu, Rong and Ding, Yiwen and Lin, Xuemei and Bai, Yufan and Kang, Qiaolin and Song, Pingxian and Zhang, Yong},
  title = {Bugbanosides from Cimicifuga racemosa target cyclin-dependent kinase 1 degradation to trigger PANoptosis in liver cancer},
  journal = {Eurasian Journal of Medicine and Oncology},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {026110127},
  doi = {10.36922/ejmo026110127}
}
Kostenlos starten →